The mechanism of tumorigenesis has not been fully identified in laryngeal cancer, which accounts for one fourth of patents with head and neck tumors.Long noncoding RNA PCAT19 has been shown to participate in the prostate cancer progression. However, little is known about the role of PCAT19 in the tumorigenesis of laryngeal cancer. In our study, it was shown that the expression levels of PCAT19 was increased in laryngeal tumor tissues and associated with decreased overall survival. Using laryngeal cancer cells lines HEp-2 and AMC-HN-8, it was demonstrated that knockdown of PCAT19 decreased the cell proliferation, increased the mitochondrial respiration, and inhibited the glycolysis. In detail, it showed that the PDK4 expression and PDHE1α phosphorylation levels were decreased upon the PCAT19 knockdown.Further studies indicated that miR-182 functioned as the bridge between PCAT19 and PDK4, which could also regulate the cellular metabolism thus affecting the cell proliferation. Furthermore, it was shown that the PCAT19/ miR-182/PDK4 axis existed and regulated cell proliferation by modulating glycolysis and mitochondrial respiration. Finally, we showed that the PCAT19 knockdown decreased the tumor growth in vivo, possibly through regulating the miR-182/PDK4 axis. In conclusion, we demonstrated that lncRNA PCAT19 promoted cell proliferation and tumorigenesis by modulating the miR-182/ PDK4 axis and the metabolism balance. PCAT19 might become a promising new target for laryngeal cancer therapeutics.
K E Y W O R D Slaryngeal carcinoma, miR-182, PCAT19, pyruvate dehydrogenase kinase 4, tumor metabolism
| INTRODUCTIONLaryngeal carcinoma is the most prevalent tumor type among head and neck cancers, which accounts for 25% to 30% of all cases. 1 In clinical settings, early-stage laryngeal carcinomas have the cure rate of 80% to 90%, whereas patients with advanced-stage tumors have only a 60% chance of cure. 2 Generally, surgical resection was accepted as the most effective treatment strategy for patients with early-stage laryngeal carcinoma. 3 However, most of the patients with laryngeal carcinoma were diagnosed with advanced-stage metastasis, since no early and effective diagnosis biomarker was available. 4,5 In total, the 5-year overall survival rate of laryngeal carcinoma is less than 60%. 6,7 Therefore, identifying key molecules and biomarkers involved in the initiation and